Table 1.
Patient characteristics (N=51)
| Variable | All Patients (n=51) |
|---|---|
| Sex | |
| Male | 16 (31) |
| Female | 35 (69) |
| Age, years | 64 (55-71.5) |
| Smoking history | |
| Ever | 24 (47) |
| Never | 27 (53) |
| FEV1, % | 104 (88-107) |
| DLCO, % | 94 (82-103) |
| Targeted mutation type | |
| EGFR exon 19 deletion | 27 (53) |
| EGFR L858R | 19 (37) |
| ALK fusion | 5 (10) |
| cTNM stage | |
| I | 14 (27) |
| II | 12 (24) |
| III | 25 (49) |
| Surgical approach | |
| Open | 31 (61) |
| Minimally invasive or VATS | 20 (39) |
| Surgical procedure | |
| Wedge resection | 1 (2) |
| Lobectomy | 46 (90) |
| Bilobectomy | 1 (2) |
| Pneumonectomy | 3 (6) |
| ypTNM stage | |
| 0 | 2 (4) |
| I | 21 (41) |
| II | 9 (18) |
| III | 18 (35) |
| IV | 1 (2) |
| Adjuvant systemic therapy | |
| Any adjuvant systemic therapy | 44 (86) |
| Targeted therapy (+/− chemotherapy) | 37 (73) |
Data are no. of patients (%) or median (interquartile range). cTNM, clinical tumor, node, metastasis; DLCO, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 second; VATS, video-assisted thoracic surgery; ypTNM, pathologic tumor, node, metastasis after therapy.